SCHEMBL6414923

SCHEMBL6414923

NN=C(c1ccc(O)cc1O)c1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
DDX3X O00571 1/20 0.35
PIM1 P11309 2/20 0.35
MAPT P10636 9/20 0.35
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 3/20 0.34
GAA P10253 9/20 0.34
MEN1 O00255 8/20 0.34
KMT2A Q03164 8/20 0.34
ALDH1A1 P00352 5/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 4/20 0.34
GFER P55789 2/20 0.34
LMNA P02545 2/20 0.34
TDP1 Q9NUW8 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414910 1.00 CYP3A4 (0.38) CYP3A4CYP1A2CYP2D6ESR1ESR2
SCHEMBL6417241 0.89 SMN1; SMN2 (0.43) ESR1ESR2MAPTTP53SMN1; SMN2
SCHEMBL6417228 0.89 SMN1; SMN2 (0.43) ESR1ESR2MAPTTP53SMN1; SMN2
SCHEMBL6419807 0.89 TP53 (0.40) ESR1ESR2PIM1MAPTTP53
SCHEMBL6431548 0.89 AKR1C3 (0.38) CYP3A4CYP1A2CYP2D6MAPTSMN1; SMN2
SCHEMBL6431540 0.89 AKR1C3 (0.38) CYP3A4CYP1A2CYP2D6MAPTSMN1; SMN2
SCHEMBL6419800 0.89 TP53 (0.40) ESR1ESR2PIM1MAPTTP53
SCHEMBL6432637 0.89 TP53 (0.35) PIM1MAPTTP53SMN1; SMN2POLB
SCHEMBL6432628 0.89 TP53 (0.35) PIM1MAPTTP53SMN1; SMN2POLB
SCHEMBL6416484 0.85 MAPT (0.36) ESR1ESR2MAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 CYP3A4 52/4885CYP1A2 65/4885CYP2D6 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.